These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9292508)

  • 1. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection.
    Diamond DJ; York J; Sun JY; Wright CL; Forman SJ
    Blood; 1997 Sep; 90(5):1751-67. PubMed ID: 9292508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice.
    Lenfant F; Pizzato N; Liang S; Davrinche C; Le Bouteiller P; Horuzsko A
    J Gen Virol; 2003 Feb; 84(Pt 2):307-317. PubMed ID: 12560562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
    Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
    J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.
    Masuoka M; Yoshimuta T; Hamada M; Okamoto M; Fumimori T; Honda J; Oizumi K; Itoh K
    Viral Immunol; 2001; 14(4):369-77. PubMed ID: 11792066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.
    Hebart H; Daginik S; Stevanovic S; Grigoleit U; Dobler A; Baur M; Rauser G; Sinzger C; Jahn G; Loeffler J; Kanz L; Rammensee HG; Einsele H
    Blood; 2002 May; 99(10):3830-7. PubMed ID: 11986243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.
    La Rosa C; Wang Z; Brewer JC; Lacey SF; Villacres MC; Sharan R; Krishnan R; Crooks M; Markel S; Maas R; Diamond DJ
    Blood; 2002 Nov; 100(10):3681-9. PubMed ID: 12393676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.
    Akiyama Y; Maruyama K; Mochizuki T; Sasaki K; Takaue Y; Yamaguchi K
    Immunol Lett; 2002 Aug; 83(1):21-30. PubMed ID: 12057851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.
    Kuzushima K; Hayashi N; Kimura H; Tsurumi T
    Blood; 2001 Sep; 98(6):1872-81. PubMed ID: 11535524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
    Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
    J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple and efficient method of generating HCMV pp65-specific T cells using overlapping peptides.
    Hwang SU; Lee JH; Choi SY; Lee YT; Park SY; Lee HS; Jae JW; Jung NC; Wang Y; Lim DS
    Acta Virol; 2020; 64(4):470-479. PubMed ID: 33151741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of Chinese specific human cytomegalovirus polyepitope recombinant vaccine.
    Zhao P; Ma DX; Yu S; Xue FZ; Zhu WW; Shao N; Zhang JR; Ji CY
    Antiviral Res; 2012 Feb; 93(2):260-269. PubMed ID: 22197248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus.
    Frankenberg N; Pepperl-Klindworth S; Meyer RG; Plachter B
    Virology; 2002 Apr; 295(2):208-16. PubMed ID: 12033779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA-A*2402-restricted HCMV immediate early-1 (IE-1) epitopes as targets for CD8+ HCMV-specific cytotoxic T lymphocytes.
    Lim JB; Kim HO; Jeong SH; Ha JE; Jang S; Lee SG; Lee K; Stroncek D
    J Transl Med; 2009 Aug; 7():72. PubMed ID: 19698161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells.
    Provenzano M; Mocellin S; Bettinotti M; Preuss J; Monsurrò V; Marincola FM; Stroncek D
    J Immunother; 2002; 25(4):342-51. PubMed ID: 12142557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of HLA-A*0201-restricted T cell responses by natural polymorphism in the IE1(315-324) epitope of human cytomegalovirus.
    Prod'homme V; Retière C; Imbert-Marcille BM; Bonneville M; Hallet MM
    J Immunol; 2003 Feb; 170(4):2030-6. PubMed ID: 12574373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition.
    Jouand N; Bressollette-Bodin C; Gérard N; Giral M; Guérif P; Rodallec A; Oger R; Parrot T; Allard M; Cesbron-Gautier A; Gervois N; Charreau B
    PLoS Pathog; 2018 Apr; 14(4):e1007041. PubMed ID: 29709038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
    Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
    Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.